ASH 2017 – Sunday, December 10

Oral Presentations

7:30AM
Navneet Majhail, MD, MS
Building C, Level 2, C211-C213
Individualized treatment summaries and survivorship care plans for hematopoietic cell transplant survivors reduced cancer treatment distress in a randomized multicenter study

7:45AM
Sudipto Mukherjee, MD, MPH
Building B, Level 2, B206
Survival among acute myeloid leukemia patients conditional on years already survived and relative to the general population in the United States

8:30AM
Brian T. Hill, MD, PhD
Building B, Level 4, B401-B402
Consolidation with autologous hematopoietic cell transplant in first remission improves overall survival in younger patients with mantle cell lymphoma in the rituximab era

8:30AM
Sudipto Mukherjee, MD, MPH
Building B, Level 2, B206
Survival among acute lymphocytic leukemia patients conditional on years already survived and relative to the general population in the United States

8:45AM
Eric Hsi, MD
Building B, Level 4, B401-402
The role of upfront hematopoietic stem cell transplantation (HSCT) in peripheral T-Cell lymphoma (PTCL) Patients in complete remission (CR) with a special focus on nodal PTCL: Report from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE), a prospective multicenter cohort study

10AM
Deepa Jagadeesh, MD
Building A, Level 4, Marcus Auditorium
Gray zone lymphoma (GZL) with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL): A pathologic consensus study with patient outcomes and prognostication across 15 North American centers

10:30AM
Brian T. Hill, MD, PhD
Building A, Level 4, Marcus Auditorium
Multicenter retrospective study of features and outcomes of patients with intravascular DLBCL treated at academic institutions within the United States

12PM
Jaroslaw Maciejewski, MD, PhD
Building B, Level 3, B312-B314
High rates of atherosclerotic disease-related mortality in myelodysplastic syndromes and chronic myelomonocytic leukemia patients associated with TET2 mutations

12:15PM
Mikkael Sekeres, MD, MS
Building B, Level 3, B312-B314
The use of immunosuppressive therapy (IST) in patients with the myelodysplastic syndromes (MDS): Clinical outcomes and their predictors in a large international patient cohort

12:45PM
Mikkael Sekeres, MD, MS
Building B, Level 3, B312-B314
Mutational signatures associated with intensity and duration of smoking in myelodysplastic syndromes (MDS)

4:45PM
Betty Hamilton, MD
Building B, Level 2, B206
Prevalence and risk-factors for financial burden in patients with chronic graft-versus-host disease: A cross-sectional survey from the Chronic GVHD Consortium

5:15PM
Sudipto Mukherjee, MD
Building B, Level 2, B206
Predictors for recurrent 30-day unplanned readmissions in patients with hematologic malignancies

5:30PM
Eric Hsi, MD
Building C, Level 1, Hall C1
Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib induction and maintenance therapy in patients with previously untreated high risk follicular lymphoma (FL): Results from CALGB 50904 (Alliance)

Poster Presentations

6 to 8PM
Building A, Level 1, Hall A2

Navneet Majhail, MD , MS
Conditional long-term survival among diffuse large B-cell lymphoma patients treated with autologous hematopoietic cell transplantation

Hypomethylating agents in patients with relapsed and refractory acute myeloid leukemia: Transplant outcomes post HMA therapy in a large international patient cohort

Keith McCrae, MD
High molecular weight kininogen alters the tumor microenvironment and reduces tumor stem cell content

Cancer cell-derived extracellular vesicles are prothrombotic in an in vitro vessel model

A novel immunoblot assay to detect contact activation in patients with cancer

Alok Khorana, MD
Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting: The Cleveland Clinic experience

Aaron Gerds, MD
Patient-reported symptom burden and peripheral blood counts among patients with polycythemia vera: an analysis from the REVEAL study

Mikkael Sekeres, MD, MS
Preliminary results from an open-label, phase 2 study of tipifarnib in chronic myelomonocytic leukemia (CMML)

Early results from a biomarker-directed phase 2 trial of SY-1425 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) demonstrate DHRS3 induction and myeloid differentiation following SY-1425 treatment

No excess risk of second malignancies in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs)

Prediction of clinically relevant mutations in myelodysplastic syndromes (MDS): A report on behalf of the MDS Clinical Research Consortium (CRC)

Hetty Carraway, MD, MBA
Distinct clinical phenotypes of patients with myeloid neoplasms carrying SF3B1 hotspot mutations

Sudipto Mukherjee, MD
Atherosclerotic arterial disease-related mortality in chronic myeloid patients treated with tyrosine kinase inhibitors

Association of tyrosine kinase inhibitors with vascular adverse events: A cohort study using pooled electronic health record

Model heterogeneity in predicting outcomes of patients with myelodysplastic syndromes (MDS)

Anjali Advani, MD
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1

Inotuzumab ozogamicin (InO) for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) in the global phase 3 INO-VATE trial: Efficacy by MLL status

Inotuzumab ozogamicin (InO) vs standard of care (SC) in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): Long-term results of the phase 3 INO-VATE study

Characteristics, mutation profiles and outcomes of patients with acute myeloid leukemia and a history of autoimmune disease

Jaroslaw Maciejewski, MD, PgD
Surveillance of the immune repertoire of aplastic anemia patients using deep sequencing

How somatic mutations carve morphologic imprint in MDS

Aziz Nazha, MD
Mutational burden before and after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia

Deepa Jagadeesh, MD
Outcomes in patients with enteropathy-associated T-cell lymphoma (EATL) and hepatosplenic T-Cell lymphoma (HSTCL): A population-based analysis using the SEER data

Brian T. Hill, MD, PhD
Marked re-expansion of chimeric antigen receptor (CAR) T cells and tumor regression following nivolumab treatment in a patient treated with axicabtagene ciloleucel (axi-cel; KTE-C19) for refractory diffuse large B Cell lymphoma (DLBCL)

Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab (BR) for follicular lymphoma: A real world analysis across 13 US cancer centers

please post as soon as possible – week of 11/27